Elexacaftor/Tezacaftor/Ivacaftor Improves Sinonasal Disease in Young Patients With Cystic Fibrosis

Strategic Insights -

Research at Agia Sofia Children's Hospital in Athens, Greece, has found that the triple therapy of elexacaftor, tezacaftor, and ivacaftor (ETI) significantly improves sinonasal disease in young patients with cystic fibrosis. The study, which involved 15 patients, ages 14 to 20, found a statistically significant improvement in nasal endoscopy findings after a median period of 3 months of treatment.

Key Takeaways:

  • The study aimed to evaluate the effect of ETI therapy on children and adolescents under 20 years of age with cystic fibrosis and concurrent chronic rhinosinusitis.
  • A total of 15 patients participated in the study, with a median age of 18 years, ranging from 14 to 20 years, and a male-to-female ratio of 46.7% to 53.3%.
  • Analysis of the modified Lund-Kennedy scores revealed a statistically significant improvement after a median period of 3 months of treatment.
  • The study found that the ETI therapy resulted in a statistically significant improvement in sinonasal disease as assessed by nasal endoscopy, but did not seem to improve the quality of life for CF patients experiencing rhinosinusitis symptoms.

Statistics:

  • 15 patients participated in the study with a median age of 18 years (range 14-20 years).
  • 7 patients (46.7%) were male, and 8 (53.3%) were female.
  • The analysis of the modified Lund-Kennedy scores revealed a statistically significant improvement after a median period of 3 months of treatment (p = 0.002).
  • The analysis of the SNOT-22 scores before and after treatment showed no statistically significant difference (p = 0.325).

Sources:

  • Elexacaftor/Tezacaftor/Ivacaftor Improves Sinonasal Disease in Young Patients With Cystic Fibrosis: A Prospective Study. Annals of Otology, Rhinology & Laryngology, 2025:34894251374839.
  • Sage Publications Inc, 2455 Teller Rd, Thousand Oaks, CA 91320, USA (publisher of Annals of Otology, Rhinology & Laryngology).
  • Ioanna Zarkada, Cystic Fibrosis Department, Agia Sofia Children's Hospital, Athens, Greece (contact for additional information).